<DOC>
	<DOCNO>NCT00756418</DOCNO>
	<brief_summary>A clinical study explore safety efficacy montelukast compare safety efficacy montelukast theophylline pediatric bronchial asthma patient use conjunction inhaled steroid .</brief_summary>
	<brief_title>Montelukast Post-marketing Comparative Study With Theophyline Added Inhaled Corticosteroid ( 0476-396 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Pediatric Bronchial Asthma Patients Aged 6 To 14 Years ( At The Beginning Of The Treatment Period ) The Severity Must Be Mild , Moderate Or Severe , Persistent Bronchial Asthma The Patient Must Have Symptoms That Can Be Used As Efficacy Variables ( Such As Repeated Coughing And Mild Or Moderate Asthma Attacks ) During The Observation Period , And Must Be Using Inhaled Steroids Patient Using AntiAsthma Treatment Or Therapy Including corticosteroid Or Oral AntiAllergic Drugs Patient With Complications That Will Impair The Judgment Of Efficacy Of This Drug Patient With Convulsive Disorders Such As Epilepsy Or Such A History Patient With Liver Disease , Renal Impairment , Heart Disease Or Such Other Complication</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>